1990
DOI: 10.1128/iai.58.10.3293-3299.1990
|View full text |Cite
|
Sign up to set email alerts
|

Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae

Abstract: Pneumococcal surface protein A (PspA) has been shown previously to elicit antibodies protective against pneumococcal infection and to be necessary for full pneumococcal virulence in mice. The protein was originally defined by the two mouse monoclonal antibodies Xi64 and Xi126, which together recognized PspA on 14% of pneumococcal isolates. Some PspA molecules reacted with both antibodies, but most reacted with only one or the other. In the present study we demonstrated that PspA is produced by all pneumococci,… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

6
107
0
3

Year Published

1997
1997
2009
2009

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 238 publications
(116 citation statements)
references
References 16 publications
6
107
0
3
Order By: Relevance
“…The speci垄city was determined by immunoblot and dot blot reaction patterns against pneumococci and other Gram-positive bacteria as well as Gram-negative bacteria. The mAb 180,C-1 showed several bands in each reacting strain and a strain to strain variation in the molecular size of PspA ; in accordance with what is reported for other mAbs against this protein [17]. Because PspA is an antigenically variable protein [17], the epitope for mAb 180,C-1 was detected in only 19 out of 76 examined S. pneumoniae strains.…”
Section: Monoclonal Antibodiessupporting
confidence: 86%
See 2 more Smart Citations
“…The speci垄city was determined by immunoblot and dot blot reaction patterns against pneumococci and other Gram-positive bacteria as well as Gram-negative bacteria. The mAb 180,C-1 showed several bands in each reacting strain and a strain to strain variation in the molecular size of PspA ; in accordance with what is reported for other mAbs against this protein [17]. Because PspA is an antigenically variable protein [17], the epitope for mAb 180,C-1 was detected in only 19 out of 76 examined S. pneumoniae strains.…”
Section: Monoclonal Antibodiessupporting
confidence: 86%
“…The mAb 180,C-1 showed several bands in each reacting strain and a strain to strain variation in the molecular size of PspA ; in accordance with what is reported for other mAbs against this protein [17]. Because PspA is an antigenically variable protein [17], the epitope for mAb 180,C-1 was detected in only 19 out of 76 examined S. pneumoniae strains. The negative control mAb 184,F-12 (IgG3) reacts with the P1.16 epitope on meningococcal class 1 protein [18].…”
Section: Monoclonal Antibodiessupporting
confidence: 86%
See 1 more Smart Citation
“…Among the pneumococcal proteins identified as potential vaccine antigens, the pneumococcal surface protein A (PspA) and the pneumococcal surface adhesin A (PsaA) are promising candidates. PspA inhibits complement deposition on pneumococci [5], is essential for full virulence of pneumococci [6], and is present on all clinically important pneumococcal strains [7]. Immunization with a recombinant PspA derived from strain Rx1 has been shown to be safe and to induce a broadly cross-reactive immune response in humans [3].…”
Section: Introductionmentioning
confidence: 99%
“…mAbs are useful tools for such analyses. PspA has been identi垄ed by over 12 mAbs [10], but these mAbs are raised against a few strains [14,15]. Most of the mAbs were produced after immunisation of XiD (X-linked immunode垄cient CBA/ N) mice which do not make antibodies to polysaccharide antigens.…”
Section: Introductionmentioning
confidence: 99%